Duodenal mucosal risk markers in patients with familial adenomatous polyposis: Effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Van Heumen, Bjorn W H ^a   Roelofs, Hennie M J ^a   Te Morsche, René H M ^a   Nagengast, Fokko M ^a   Peters, Wilbert H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Caspase 3; Celecoxib; Duodenal adenomatosis; Duodenal mucosa; Familial adenomatous polyposis (FAP); Glutathione S transferase Alpha; Risk markers; Ursodeoxycholic acid

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; CASPASE 3; CELECOXIB; CYCLIN D1; CYCLOOXYGENASE 2; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE P1; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PLACEBO; URSODEOXYCHOLIC ACID; UVOMORULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DUODENUM MUCOSA; DYSPEPSIA; DYSPLASIA; ENZYME BLOOD LEVEL; FAMILIAL COLON POLYPOSIS; FEMALE; FOLLOW UP; HUMAN; IRON DEFICIENCY ANEMIA; MALE; MALIGNANT TRANSFORMATION; METAPLASIA; NUCLEOTIDE SEQUENCE; PEROXISOME; RISK FACTOR;

ADENOMATOUS POLYPOSIS COLI; ADULT; AGED; CADHERINS; CASPASE 3; CYCLOOXYGENASE 2; DUODENAL NEOPLASMS; FEMALE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROTEINS; PYRAZOLES; SULFONAMIDES; URSODEOXYCHOLIC ACID; YOUNG ADULT;

EID: 84887691948     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-181     Document Type: Article

References (42)

1. Localization of the gene for familial adenomatous polyposis on chromosome 5. Bodmer WF, Bailey CJ, Bodmer J, Bussey HJ, Ellis A, Gorman P, Lucibello FC, Murday VA, Rider SH, Scambler P, Sheer D, Solomon E, Spurr NK, Nature 1987 328 614 616 10.1038/328614a0 3039373 (Pubitemid 17103960)
2. Results of national registration of familial adenomatous polyposis. Bulow S, Gut 2003 52 742 746 10.1136/gut.52.5.742 12692062 (Pubitemid 36528879)
3. Changing causes of mortality in patients with familial adenomatous polyposis. Belchetz LA, Berk T, Bapat BV, Cohen Z, Gallinger S, Dis Colon Rectum 1996 39 384 387 10.1007/BF02054051 8878496 (Pubitemid 26116866)
4. Evaluating causes of death in familial adenomatous polyposis. de Campos FG, Perez RO, Imperiale AR, Seid VE, Nahas SC, Cecconello I, J Gastrointest Surg 2010 14 1943 1949 10.1007/s11605-010-1288-6 20676788
5. Duodenal adenomatosis in familial adenomatous polyposis. Bulow S, Bjork J, Christensen IJ, Fausa O, Jarvinen H, Moesgaard F, Vasen HF, Gut 2004 53 381 386 10.1136/gut.2003.027771 14960520 (Pubitemid 38241334)
6. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Vasen HF, Bulow S, Myrhoj T, Mathus-Vliegen L, Griffioen G, Buskens E, Taal BG, Nagengast FM, Slors JF, de Ruiter P, Gut 1997 40 716 719 10.1136/gut.40.6.716 9245923 (Pubitemid 27305462)
7. Duodenal surveillance improves the prognosis after duodenal cancer in familial adenomatous polyposis. Bulow S, Christensen IJ, Hojen H, Bjork J, Elmberg M, Jarvinen H, Lepisto A, Nieuwenhuis M, Vasen H, Colorectal Dis 2012 14 947 952 10.1111/j.1463-1318.2011.02844.x 21973191
8. Features of duodenal cancer in patients with familial adenomatous polyposis. Latchford AR, Neale KF, Spigelman AD, Phillips RK, Clark SK, Clin Gastroenterol Hepatol 2009 7 659 663 10.1016/j.cgh.2009.02.028 19281862
9. Surgical management for advanced duodenal denomatosis and duodenal cancer in Dutch patients with familial adenomatous polyposis: a nationwide retrospective cohort study. van Heumen BW, Nieuwenhuis MH, van Goor H, Mathus-Vliegen EM, Dekker E, Gouma DJ, Dees J, van Eijck CH, Vasen HF, Nagengast FM, Surgery 2012 151 681 690 10.1016/j.surg.2011.12.008 22265391
10. The many faces of the tumor suppressor gene APC. van Es JH, Giles RH, Clevers HC, Exp Cell Res 2001 264 126 134 10.1006/excr.2000.5142 11237529 (Pubitemid 32989087)
11. The ABC of APC. Fearnhead NS, Britton MP, Bodmer WF, Hum Mol Genet 2001 10 721 733 10.1093/hmg/10.7.721 11257105 (Pubitemid 32331581)
12. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Tetsu O, McCormick F, Nature 1999 398 422 426 10.1038/18884 10201372 (Pubitemid 29180374)
13. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. He TC, Chan TA, Vogelstein B, Kinzler KW, Cell 1999 99 335 345 10.1016/S0092-8674(00)81664-5 10555149 (Pubitemid 29519912)
14. APC, signal transduction and genetic instability in colorectal cancer. Fodde R, Smits R, Clevers H, Nat Rev Cancer 2001 1 55 67 10.1038/35094067 11900252 (Pubitemid 33741881)
15. Transcriptome profile of human colorectal adenomas. Sabates-Bellver J, van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H, Laczko E, Kurowski MA, Bujnicki JM, Menigatti M, Luz J, Ranalli TV, Gomes V, Pastorelli A, Faggiani R, Anti M, Jiricny J, Clevers H, Marra G, Mol Cancer Res 2007 5 1263 1275 10.1158/1541-7786.MCR-07-0267 18171984
16. Clinicopathologic significance of KIAA1199 overexpression in human gastric cancer. Matsuzaki S, Tanaka F, Mimori K, Tahara K, Inoue H, Mori M, Ann Surg Oncol 2009 16 2042 2051 10.1245/s10434-009-0469-6 19434458
17. Wnt signalling in stem cells and cancer. Reya T, Clevers H, Nature 2005 434 843 850 10.1038/nature03319 15829953 (Pubitemid 40558990)
18. Role of cyclooxygenase-2 in colorectal cancer. Sinicrope FA, Gill S, Cancer Metastasis Rev 2004 23 63 75 15000150 (Pubitemid 38221596)
19. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A, Carcinogenesis 2009 30 377 386 10.1093/carcin/bgp014 19136477
20. Celecoxib for the prevention of colorectal adenomatous polyps. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B, N Engl J Med 2006 355 885 895 10.1056/NEJMoa061652 16943401 (Pubitemid 44315981)
21. Celecoxib for the prevention of sporadic colorectal adenomas. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET, N Engl J Med 2006 355 873 884 10.1056/NEJMoa061355 16943400 (Pubitemid 44315980)
22. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, N Engl J Med 2000 342 1946 1952 10.1056/NEJM200006293422603 10874062 (Pubitemid 30419089)
23. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G, Gut 2002 50 857 860 10.1136/gut.50.6.857 12010890 (Pubitemid 34539050)
24. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre randomized controlled trial. van Heumen BW, Roelofs HMJ, Vink-Börger ME, Dekker E, Mathus-Vliegen EM, Dees J, Koornstra JJ, Langers AM, Nagtegaal ID, Kampman E, Peters WHM, Nagengast FM, Orphanet J Rare Dis 2013 8 118 10.1186/1750-1172-8-118 23919274
25. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, Lance P, J Natl Cancer Inst 2005 97 846 853 10.1093/jnci/dji144 15928305 (Pubitemid 40909127)
26. Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Jacoby RF, Cole CE, Hawk ET, Lubet RA, Gastroenterology 2004 127 838 844 10.1053/j.gastro.2004.06.003 15362039 (Pubitemid 39208416)
27. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD, Gastroenterology 2003 124 889 893 10.1053/gast.2003.50156 12671884 (Pubitemid 36389790)
28. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA, Ann Intern Med 2001 134 89 95 10.7326/0003-4819-134-2-200101160-00008 11177311 (Pubitemid 32096335)
29. Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Wali RK, Khare S, Tretiakova M, Cohen G, Nguyen L, Hart J, Wang J, Wen M, Ramaswamy A, Joseph L, Sitrin M, Brasitus T, Bissonnette M, Cancer Epidemiol Biomarkers Prev 2002 11 1653 1662 12496057 (Pubitemid 36020020)
30. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK, Lancet 1989 2 783 785 2571019 (Pubitemid 19234818)
31. Glutathione transferases. Hayes JD, Flanagan JU, Jowsey IR, Annu Rev Pharmacol Toxicol 2005 45 51 88 10.1146/annurev.pharmtox.45.120403.095857 15822171 (Pubitemid 40261798)
32. Low colonic glutathione detoxification capacity in patients at risk for colon cancer. Grubben MJ, van den Braak CC, Nagengast FM, Peters WHM, Eur J Clin Invest 2006 36 188 192 10.1111/j.1365-2362.2006.01618.x 16506964 (Pubitemid 43341270)
33. Detoxification enzymes in the duodenal mucosa of patients with familial adenomatous polyposis. Berkhout M, Roelofs HMJ, Friederich P, van Krieken JHJM, Nagengast FM, Peters WHM, Br J Surg 2005 92 754 755 10.1002/bjs.4996 15856485 (Pubitemid 40863198)
34. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S, Biochem Pharmacol 2004 67 1469 1478 10.1016/j.bcp.2003.12.014 15041464 (Pubitemid 38388209)
35. Cyclooxygenase-2 expression in human esophageal carcinoma. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K, Cancer Res 1999 59 198 204 9892207 (Pubitemid 29062978)
36. Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Tatsuguchi A, Matsui K, Shinji Y, Gudis K, Tsukui T, Kishida T, Fukuda Y, Sugisaki Y, Tokunaga A, Tajiri T, Sakamoto C, Hum Pathol 2004 35 488 495 10.1016/j.humpath.2003.10.025 15116331 (Pubitemid 38507087)
37. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN, Gastroenterology 1994 107 1183 1188 7926468 (Pubitemid 24294584)
38. Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine. von Rahden BH, Brucher BL, Langner C, Siewert JR, Stein HJ, Sarbia M, Br J Surg 2006 93 1424 1432 10.1002/bjs.5426 17022010 (Pubitemid 44736095)
39. Ursodeoxycholic acid intervention in patients with familial adenomatous polyposis: a pilot study. Berkhout M, Roelofs HMJ, Friederich P, van Schaik A, Gosens MJ, Marian B, Pool-Zobel BL, van Krieken JHJM, Peters WHM, Nagengast FM, Transl Res 2007 150 147 149 10.1016/j.trsl.2007.03.009 17761365 (Pubitemid 47302971)
40. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G-> C COX-2 polymorphism. Brosens LA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FH, Hylind LM, Offerhaus GJ, Giardiello FM, Goggins M, Clin Cancer Res 2005 11 4090 4096 10.1158/1078-0432.CCR-04-2379 15930344 (Pubitemid 40791573)
41. E-cadherin expression is homogeneously reduced in adenoma from patients with familial adenomatous polyposis: an immunohistochemical study of E-cadherin, beta-catenin and cyclooxygenase-2 expression. Jungck M, Grunhage F, Spengler U, Dernac A, Mathiak M, Caspari R, Friedl W, Sauerbruch T, Int J Colorectal Dis 2004 19 438 445 14986031 (Pubitemid 39193809)
42. Loss of extracellular E-cadherin in the normal mucosa of duodenum and colon of patients with familial adenomatous polyposis. Berkhout M, Gosens MJ, Brouwer KM, Peters WHM, Nagengast FM, van Krieken JHJM, Nagtegaal ID, Hum Pathol 2006 37 1389 1399 10.1016/j.humpath.2006.05.018 16949915 (Pubitemid 44584332)